Abstract
Age-related macular degeneration (AMD) is the most common cause of blindness among the elderly in the developed world. While treatment is effective for the neovascular or “wet” form of AMD, no therapy is successful for the non-neovascular or “dry” form. Here we discuss the current knowledge on dry AMD pathobiology and propose future research directions that would expedite the development of new treatments. In our view, these should emphasize system biology approaches that integrate omic, pharmacological, and clinical data into mathematical models that can predict disease onset and progression, identify biomarkers, establish disease causing mechanisms, and monitor response to therapy.
| Original language | English (US) |
|---|---|
| Article number | 3347 |
| Journal | Nature communications |
| Volume | 10 |
| Issue number | 1 |
| DOIs | |
| State | Published - Dec 1 2019 |
Fingerprint
ASJC Scopus subject areas
- Chemistry(all)
- Biochemistry, Genetics and Molecular Biology(all)
- Physics and Astronomy(all)
Cite this
A systems biology approach towards understanding and treating non-neovascular age-related macular degeneration. / Handa, James; Bowes Rickman, Cathy; Dick, Andrew D.; Gorin, Michael B.; Miller, Joan W.; Toth, Cynthia A.; Ueffing, Marius; Zarbin, Marco; Farrer, Lindsay A.
In: Nature communications, Vol. 10, No. 1, 3347, 01.12.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A systems biology approach towards understanding and treating non-neovascular age-related macular degeneration
AU - Handa, James
AU - Bowes Rickman, Cathy
AU - Dick, Andrew D.
AU - Gorin, Michael B.
AU - Miller, Joan W.
AU - Toth, Cynthia A.
AU - Ueffing, Marius
AU - Zarbin, Marco
AU - Farrer, Lindsay A.
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Age-related macular degeneration (AMD) is the most common cause of blindness among the elderly in the developed world. While treatment is effective for the neovascular or “wet” form of AMD, no therapy is successful for the non-neovascular or “dry” form. Here we discuss the current knowledge on dry AMD pathobiology and propose future research directions that would expedite the development of new treatments. In our view, these should emphasize system biology approaches that integrate omic, pharmacological, and clinical data into mathematical models that can predict disease onset and progression, identify biomarkers, establish disease causing mechanisms, and monitor response to therapy.
AB - Age-related macular degeneration (AMD) is the most common cause of blindness among the elderly in the developed world. While treatment is effective for the neovascular or “wet” form of AMD, no therapy is successful for the non-neovascular or “dry” form. Here we discuss the current knowledge on dry AMD pathobiology and propose future research directions that would expedite the development of new treatments. In our view, these should emphasize system biology approaches that integrate omic, pharmacological, and clinical data into mathematical models that can predict disease onset and progression, identify biomarkers, establish disease causing mechanisms, and monitor response to therapy.
UR - http://www.scopus.com/inward/record.url?scp=85069643241&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069643241&partnerID=8YFLogxK
U2 - 10.1038/s41467-019-11262-1
DO - 10.1038/s41467-019-11262-1
M3 - Article
C2 - 31350409
AN - SCOPUS:85069643241
VL - 10
JO - Nature Communications
JF - Nature Communications
SN - 2041-1723
IS - 1
M1 - 3347
ER -